Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:10635
Structure:
Synonyms:
()-androstan-17beta-ol-3-one
(+)-Androstan-17beta-ol-3-one
(5-alpha,17-beta)-17-Hydroxyandrostan-3-one
(5alpha,17beta)-17-hydroxyandrostan-3-one
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12
12040-51-6
17-beta-Hydroxy-5-alpha-androstan-3-one
17-BETA-HYDROXY-5ALPHA-ANDROSTAN-3-O
17-beta-hydroxy-5alpha-androstan-3-one
17-beta-hydroxyandrostan-3-one
17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,10,11,12,13,14,15,16, 17-hexadecahydrocyclopenta[a]phenanthren-3-one
17.beta.-Hydroxy-3-androstanone
17beta-Hydroxy-3-androstanone
17beta-Hydroxy-5alpha-androstan-3-one
17beta-Hydroxy-5alpha-androstane-3-one
17beta-Hydroxyandrostan-3-one
1kdk
1t5z
1t63
1t7r
28801-96-9
4,5-alpha-Dihydrotestosterone
4,5.alpha.-Dihydrotestosterone
4,5alpha-Dihydrotestosterone
4-Dihydrotestosterone
5-alpha-Androstan-17-beta-ol-3-one
5-alpha-Androstan-3-one, 17-beta-hydroxy-
5-alpha-Dihydrotestosterone
5.alpha.,17.beta.-Hydroxyandrostan-3-one
5.alpha.-Androstan-17.beta.-ol-3-one
5.alpha.-Androstan-3-one, 17.beta.-hydroxy-
5.alpha.-Dihydrotestosterone
5.alpha.-Dihydroxytestosterone
521-18-6
5alpha dihydrotestosterone
5alpha,17beta-Hydroxyandrostan-3-one
5alpha,17eta-Hydroxyandrostan-3-one
5alpha-Androstan-17beta-ol-3-one
5alpha-Androstan-3-one, 17beta-hydroxy-
5alpha-Androstan-3-one, 17beta-hydroxy- (8CI)
5alpha-Androstanolone
5alpha-Dihydrotestosterone
5alpha-Dihydroxytestosterone
A8380_SIGMA
AC-16144
AC1L1VMJ
AC1Q6OL8
Anaboleen
Anabolex
Anaprotin
Andractim
Andractim (TN)
Andrin
Androlone
Androstalone
Androstan-17b-ol-3-one
Androstan-17beta-ol-3-one
Androstan-3-one, 17-hydroxy-, (5.alpha.,17.beta.)-
androstan-3-one, 17-hydroxy-, (5alpha,17beta)-
Androstan-3-one, 17-hydroxy-, (5alpha,17beta)- (9CI)
Androstanolona
Androstanolona [INN-Spanish]
Androstanolone
Androstanolone (INN)
Androstanolonum
Androstanolonum [INN-Latin]
BB_NC-0075
BIDD:ER0136
BIDD:PXR0075
C03917
C19H30O2
CHEBI:16330
CHEMBL27769
CMC_13452
Cristerona MB
D07456
DEA No. 4000
DHT
Dihydrotestosteron
Dihydrotestosterone
EINECS 208-307-3
HMS2272H05
LG 152
LMST02020042
LS-19384
MLS001304063
MolPort-002-506-880
NCGC00091013-01
NCGC00091013-02
NCGC00091013-03
Neodrol
NSC 10972
NSC10972
Proteina
Protona
SMR000058342
Stanaprol
Stanolon
STANOLONE
Stanolone [BAN]
Stanorone
Testosterone, dihydro-
UNII-08J2K08A3Y
ZINC03814360
[3H]DHT
ATC-Codes:

Target

show target details
Uniprot ID:S5A2_HUMAN
Synonyms:
3-oxo-5-alpha-steroid 4-dehydrogenase 2
5 alpha-SR2
SR type 2
Steroid 5-alpha-reductase 2
Type II 5-alpha reductase
EC-Numbers:1.3.99.5
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

18280514
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.. Donald J Tindall; Roger S Rittmaster (2008) The Journal of urology display abstract
PURPOSE: Androgens are essential for prostatic growth and development but they also have a significant role in prostate disease pathogenesis. Dihydrotestosterone, the primary prostatic androgen, is transformed from testosterone by types 1 and 2 5alpha-reductase and, thus, a potential therapeutic benefit could be achieved through the inhibition of 5alpha-reductase. MATERIALS AND METHODS: A literature review was performed using PubMed/MEDLINE and congress abstracts to examine evidence supporting the potential of 5alpha-reductase inhibitors in the primary prevention of prostate cancer and in limiting the progression of diagnosed disease. RESULTS: Prostate disease development is associated with increased expression of each 5alpha-reductase isoenzyme with over expression of type 1 of particular importance in prostate cancer development and progression. The 2 5alpha-reductase inhibitors currently clinically available are finasteride, a type 2 5alpha-reductase inhibitor, and dutasteride, a dual 5alpha-reductase inhibitor. Dual inhibition by dutasteride has been shown to translate into a greater degree and consistency of dihydrotestosterone suppression compared with finasteride. The Prostate Cancer Prevention Trial showed that finasteride significantly decreased the 7-year risk of prostate cancer in men with prostate specific antigen 3.0 ng/ml or less, while the ongoing Reduction by Dutasteride of Prostate Cancer Events study is assessing whether dutasteride decreases the risk of biopsy detectable prostate cancer in men with prostate specific antigen 2.5 to 10 ng/ml and a previous negative biopsy. Small-scale studies have demonstrated potential effects of 5alpha-reductase inhibition in prostate cancer treatment that warrant further investigation, while dutasteride use in men undergoing expectant treatment is also being examined. CONCLUSIONS: The inhibition of 5alpha-reductase represents a valid target for prostate cancer risk reduction and treatment strategies. The greater suppression of dihydrotestosterone observed with agents that inhibit each 5alpha-reductase isoenzyme may translate into enhanced outcomes and studies are under way to test this hypothesis.